CRD-BP and β-TrCP in colorectal cancer

doi:10.3760/cma.j.issn.1673-422X.2013.12.016

Abstract

Abstract: Coding region instability determinant (CRD) is one of the influence factors of oncogene cmyc. Coding region instability determinantbinding protein (CRDBP) can connect with CRD in order to protect CRD from nuclease attack, prevent rapid degradation of cmyc mRNA, and increase cmyc protein content. Betatransducin repeatscontaining protein (βTrCP) can affect cell growth, differentiation, apoptosis and oncogenesis by regulating multiple signaling pathways and cell cycle. The overexpression of CRDBP can upregulate the expression of βTrCP and both of them play important roles in the tumorigenesis, progression, metastasis and invasion of colorectal cancer.

Key words: Colorectal neoplasms, Signal transduction, Coding region instability determinant-binding protein, Beta-transducin repeats-containing protein

CHENG Li, CHENG Li, JIA Dan-Dan, QI Wen-Juan, ZHOU Chang-Jiang. CRD-BP and β-TrCP in colorectal cancer[J]. Journal of International Oncology, 2013, 40(12): 930-932.

References

［1］ Harnicareva A, Kozubek S, Pachernik J, et al. Distinct nuclear arrangement of active and inactive cmyc genes in control and differentiated colon carcinoma cells. Exp Cell Res, 2006, 312(20): 40194035. ［2］ Mongroo PS, Noubissi FK, Cuatrecasas M, et al. IMP1 displays crosstalk with KRas and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2. Cancer Res, 2011, 71(6): 21722182. ［3］王方金, 何蕴韶, 张常华, 等. 巢式荧光实时RTPCR检测结直肠癌患者外周血中CRDBP mRNA. 临床检验杂志, 2005, 23(2): 120122. ［4］王启远, 李坤, 胡波, 等. 直肠癌组织crdbp表达及临床意义的研究. 中华肿瘤防治杂志, 2010, 17(12): 930932. ［5］ Dimitriadis E, Trangas T, Milatos S, et al. Expression of oncofetal RNAbinding protein CRDBP/IMP1 predicts clinical outcome in colon cancer. Int J Cancer, 2007, 121(3): 486494. ［6］ Hamilton KE, Noubissi FK, Katti PS, et al. IMP1 promotes tumor growth, dissemination, and a tumorinitiating cell phenotype in colorectal cancer cell xenografts. Carcinogenesis, 2013, In press. ［7］ Craig EA, Weber JD, Spiegelman VS. Involvement of the mRNA binding protein CRDBP in the regulation of metastatic melanoma cell proliferation and invasion by hypoxia. J Cell Sci, 2012, 125(Pt 24): 59505954. ［8］ Goswaimi S, Tarapore RS, Teslaa JJ, et al. MicroRNA340mediated degradation of microphthalmiaassociated transcription factor mRNA is inhibited by the coding region determinantbinding protein. J Biol Chem, 2010, 285(27): 2053220540. ［9］ Craig EA, Spiegelman VS. Inhibition of coding region determinant binding protein sensitizes melanoma cells to chemotherapeutic agents. Pigment Cell Melanoma Res, 2012, 25(1): 8387. ［10］ Tsai WB, Chung YM, Zou Y, et al. Inhibition of FOXO3 tumor suppressor function by betaTrCP1 through ubiquitinmediated degradation in a tumor mouse model. PLoS One, 2010, 5(7): e11171. ［11］过倩萍, 邢欣荣, 伍会健. 蛋白质修饰对wnt信号通路的调控. 中国生物化学与分子生物学报, 2009, 25(2): 110115. ［12］李坤, 侯宪琴, 胡波, 等. 直肠癌组织βcatenin和βTrcp表达及其临床意义的探讨. 中华肿瘤防治杂志, 2011, 18(24): 19481952. ［13］邓辉洲, 汪谦. βcantenin， βTrcp在肝癌和癌旁组织中的表达. 现代肿瘤学, 2008, 16(8): 13481350. ［14］ Li X, Liu J, Gao T. betaTrCPmediated ubiquitination and degradation of PHLPP1 are negatively regulated by Akt. Mol Cell Biol, 2009, 29(23): 61926205. ［15］ Lee EK, Gorospe M. Coding region, the neglected posttranscriptional code. RNA Biol, 2011, 8(1): 4448. ［16］ Lauscher JC, Grne J, Dullat S, et al. Association between activation of atypical NFkappaB1 p105 signaling pathway and nuclear betacatenin accumulation in colorectal carcinoma. Mol Carcinog, 2010, 49(2): 121129. ［17］ Noubissi FK, Nikiforov MA, Colburn N, et al. Transcriptional Regulation of CRDBP by cmyc: implications for cmyc functions. Genes Cancer, 2010, 1(10): 10741082. ［18］ Noubissi FK, Elcheva I, Bhatia N, et al. CRDBP mediates stabilization of betaTrCP1 and cmyc mRNA in response to betacatenin signaling. Nature, 2006， 441(7095): 898901. ［19］ Gluschnaider U, Hidas G, Cojocaru G, et al. betaTrCP inhibition reduces prostate cancer cell growth via upregulation of the aryl hydrocarbon receptor. PLoS One, 2010, 5(2): e9060. ［20］ Gu W, Katz Z, Wu B, et al. Regulation of local expression of cell adhesion and motilityrelated mRNAs in breast cancer cells by IMP1/ZBP1. J Cell Sci, 2012, 125(Pt 1): 8191. ［21］ Elcheva I, Goswami S, Noubissi FK, et al. CRDBP protects the coding region of βTrCP1 mRNA from miR183mediated degradation. Mol Cell, 2009, 35(2): 240246. ［22］ Chitnis MM, Yuen JS, Protheroe AS, et al. The type 1 insulinlike growth factor receptor pathway. Clin Cancer Res, 2008, 14(20): 63646370. ［23］ Chu PC, Kulp SK, Chen CS. Insulinlike growth factorⅠ receptor is suppressed through transcriptional repression and mRNA destabilization by a novel energy restrictionmimetic agent. Carcinogenesis, 2013, In press.

[1]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[5]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.
[6]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer [J]. Journal of International Oncology, 2023, 50(5): 268-273.
[7]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163.
[8]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[9]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722.
[10]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687.
[11]	Wang Xi, Wu Chuanqing. Research progress in reversing multidrug resistance in colorectal cancer [J]. Journal of International Oncology, 2023, 50(1): 42-46.
[12]	Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang. Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 555-559.
[13]	He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang. Predictive value of inflammatory markers in colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 560-563.
[14]	Zhao Ying, Zhang Gehong. Study on the correlations between AGR, PLR and NLR changes and chemotherapy efficacy of metastatic colorectal cancer [J]. Journal of International Oncology, 2022, 49(8): 473-477.
[15]	Huang Mengpan, Wang Xuehong, Lu Yongfu. Mechanism of FOXA2 in colorectal cancer and its application in diagnosis and treatment [J]. Journal of International Oncology, 2022, 49(8): 490-493.